1. Ex-FDA Chief Gottlieb says regulator needs to up pace on COVID-19 drugs— Gilead won't be charging for use of experimental COVID drug, for now — FDA backs first emergency COVID-19 antibody test from Cellex — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

What’s the future now for CNS2

Discussion in 'Allergan' started by anonymous, Mar 7, 2019 at 1:02 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Now that Rapastinel a flop, what’s the future for CNS2? I know the company already has about 20 in place in some markets. Don’t think need three reps selling Vraylar in same offices
     

  2. anonymous

    anonymous Guest

    Expanded before getting Phase 3 results.... good move upper management.
     
  3. anonymous

    anonymous Guest

    Bleak.
     
  4. anonymous

    anonymous Guest

    Bye bye, dummy primary care rep
     
  5. anonymous

    anonymous Guest

    A decent severance package coming your way

    A removal of the bronze handcuffs for the opportunity to find silver or gold elsewhere
     
  6. anonymous

    anonymous Guest

    What an outdated sales model to have three reps calling on psych offices. I sure hope company not stupid enough to add more CNS2 reps.
     
  7. anonymous

    anonymous Guest

     
  8. anonymous

    anonymous Guest

    very unnecessary!
     
  9. anonymous

    anonymous Guest

    Weren’t they put in place to gear up for rapastinal launch that now isn’t going to happen. Smart mover upper management. Now we apparently have a bunch of higher paid reps clogging up offices
     
  10. anonymous

    anonymous Guest


    Everything you said is correct but we aren’t higher paid reps lol
     
  11. anonymous

    anonymous Guest

    I didn’t even know there was a CNS2 position. Wonder how they decided where to put them. Must be in markets where access wide open so lucky them if that’s the case cuz I have a hard time getting to see 4 live bodies in a day the way it is.
     
  12. anonymous

    anonymous Guest


    Find another division quick
     
  13. anonymous

    anonymous Guest

    Yeah, these dopes took the job and didn’t receive a raise.
     
  14. anonymous

    anonymous Guest

    In the markets that are adding CNS2 reps, they should definitely pull the psych providers off the primary care reps panels and just pay them on primary care scripts. Let the CNS specialists who have more experience call on the psych market like every other company has done forever. Why have a CNS role if pcp reps calling on them too. Allergan way behind the times
     
  15. anonymous

    anonymous Guest

    specialty reps should be only reps calling on psych. Let the PCR reps sell to all those primary care doctors corporate thinks they are going to get to prescribe Vraylar
     
  16. anonymous

    anonymous Guest

    will the company be adding more CNS2 reps? Sounds like they would rather spend resources hiring contract people to sell Vraylar to low volume primary Care doctors. Makes no sense whatsoever. Vraylar is a specialty drug and reps selling it need to have years experience selling in CNS in order to be a respected and knowledgeable rep. What is upper management thinking???
     
  17. anonymous

    anonymous Guest

    Good lord we don’t need more bodies selling Vraylar in primary care. Such a stupid plan and waste of resources. In territories that have a CNS2 We need to remove primary care targets from their panels and have the PCR rep focus on the primary care market and take psych providers off their panels.
     
  18. anonymous

    anonymous Guest

    Is there plans to add more CNS2 reps? Seems odd there are only 20 in company right now. Thinking it’s a pilot program to see if it generates more sales
     
  19. anonymous

    anonymous Guest

    CNS Specialty Managers leaving all over??? What's up with that? That can't be a good sign...